Tag: markets

The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticosteroid use for chronic conditions further accelerates market demand. However, challenges such as high treatment costs, limited awareness in low-income regions, and diagnostic complexities may slow adoption in emerging markets. Between 2025-2035, advancements in diagnostic technologies and innovative therapies are expected to bolster market growth, though access issues remain crucial. Key players like Eton Pharmaceuticals, Antares Pharma, and Pfizer are leading with product innovation and strategic partnerships.

Award Recognition underscores the importance of AI-driven drug discovery

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and accompanying Series A Common Warrant and Series B Common Warrant and (ii) in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 3,502,335 common shares, accompanying Series A Common Warrants to purchase an aggregate of 3,502,335 common shares and accompanying Series B Common Warrants to purchase an aggregate of 3,502,335 common shares, at a combined public offering price of $1.499 per pre-funded warrant and accompanying Series A Common Warrant and Series B Common Warrant, which represents the combined public offering price for the Shares and accompanying common warrants less the $0.001 per share exercise price for each such pre-funded warrant. The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $52.5 million. The Offering is expected to close on or about July 14, 2025, subject to satisfaction of customary closing conditions.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

DALLAS, July 11, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of CSW Industrials, Inc. (NYSE: CSW) today declared a regular quarterly cash dividend of $0.27 per share. The dividend is payable on August 8, 2025, to shareholders of record as of the close of business on July 25, 2025.

Mercado Libre now holds investment grade ratings from two leading agencies with S&P following Fitech's upgrade in October 2024